6-year data confirm sustained efficacy of ofatumumab

In the treatment of active relapsing multiple sclerosis (EMR), monthly subcutaneous (sc) application has been shown to be effective^{a, b, c} Anti-CD20 antibody ofatumumab^d In the two approval studies ASCLEPIOS I and II, superior efficacy compared to basic teriflunomide therapy with comparable safety and tolerability [1]. Current results from a subgroup analysis (n=465) of the ALITHIOS open-label extension study confirm for newly diagnosed cases^{It is}treatment-naive patients, the sustained high efficacy and favorable benefit-risk profile of ofatumumab during the observation period of up to six years [2, 3]. Even with moderate activity^f RMS can be an early initiation of highly effective therapy (HET^G) may be beneficial with ofatumumab [1, 3].